May 9th 2024
Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Apatinib Plus Pegylated Liposomal Doxorubicin Yields Significant Efficacy in Advanced Ovarian Cancer
July 11th 2022Results from the phase 2 APPROVE trial showed apatinib plus pegylated liposomal doxorubicin improved efficacy and safety compared with pegylated liposomal doxorubicin alone for patients with platinum-resistant recurrent ovarian cancer.
No Difference in Survival Observed in Uterine Carcinosarcoma Following SLN Biopsy vs Systemic LND
June 15th 2022Patients with uterine carcinosarcoma who underwent sentinel lymph node biopsy or systemic lymph node dissection did not experience a difference in progression-free survival or overall survival.
FDA Approves First-Line Pembrolizumab Plus Chemo With or Without Bevacizumab for Cervical Cancer
October 13th 2021The FDA has approved the use of pembrolizumab plus chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have PD-L1 expression identified via an FDA-approved test.